News
Allakos is acquired by Concentra Biosciences.
Allakos Inc., a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, announced it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC will acquire Allakos for $0.33 in cash per share of Allakos common stock
Allakos’ Board of Directors has unanimously determined that the acquisition by Concentra is in the best interests of all Allakos shareholders and, following the unanimous recommendation of Allakos’ Transaction Committee, has approved the Merger Agreement and related transactions.
Type: industry